Company & Sponsor Intelligence
GE Healthcare
Evidence-linked intelligence derived from the current NeuroRisk clinical research corpus. Coverage reflects indexed source data and is not a claim of complete company activity.
Request enterprise analysis →Indexed trials3
Recruiting0
Completed3
Countries2
Therapeutic footprint
alzheimersparkinsons
Indexed studies
NCT04265209[18F] LBT-999 PET Compared to [123I]-FP/CIT SPECT to Distinguish Between Parkinson's Diseases and Essential Tremor
parkinsons · FrancePHASE3
parkinsons · FrancePHASE3
NCT02813070Comparison of PET Amyloid Imaging in Japanese and Western Subjects
alzheimers · PHASE2
alzheimers · PHASE2
NCT01265394Positron Emission Tomography (PET) Amyloid Imaging of the Brain in Healthy Young Adult Subjects
alzheimers · United StatesPHASE3
alzheimers · United StatesPHASE3
Intelligence layer updated: 2026-10-14 06:11:28.884102+00:00
Enterprise intelligence
Compare sponsor activity, recruiting momentum, therapeutic exposure, geography and connected research signals across the neuroscience ecosystem.
Request comparative intelligence →